Details for Patent: 9,278,096
✉ Email this page to a colleague
Which drugs does patent 9,278,096 protect, and when does it expire?
Patent 9,278,096 protects TRINTELLIX and is included in one NDA.
Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-five patent family members in thirty countries.
Summary for Patent: 9,278,096
| Title: | Therapeutic uses of compounds having combined SERT, 5-HT.sub.3 and 5-HT.sub.1A activity |
| Abstract: | New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided. |
| Inventor(s): | Dragheim; Marianne (Vedbaek, DK) |
| Assignee: | H. Lundbeck A/S (Valby, DK) Takeda Pharmaceuticals North America, Inc. (Deerfield, IL) |
| Application Number: | 12/741,780 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,278,096 |
|
Patent Claim Types: see list of patent claims | Use; |
More… ↓ |
Drugs Protected by US Patent 9,278,096
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,278,096
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2007 01607 | Nov 13, 2007 |
| Denmark | 2007 01788 | Dec 14, 2007 |
| Denmark | 2008 01300 | Sep 17, 2008 |
| PCT Information | |||
| PCT Filed | November 12, 2008 | PCT Application Number: | PCT/DK2008/050271 |
| PCT Publication Date: | May 22, 2009 | PCT Publication Number: | WO2009/062517 |
International Family Members for US Patent 9,278,096
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 069260 | ⤷ Subscribe | |||
| Austria | E537829 | ⤷ Subscribe | |||
| Australia | 2008323390 | ⤷ Subscribe | |||
| Brazil | PI0820474 | ⤷ Subscribe | |||
| Canada | 2705163 | ⤷ Subscribe | |||
| Chile | 2008003363 | ⤷ Subscribe | |||
| China | 102014908 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
